Your browser doesn't support javascript.
loading
Outcomes of patients with different lepidic percentage and tumor size of stage I lung adenocarcinoma.
Liu, Chia; Wang, Lei-Chi; Chen, Hui-Shan; Yeh, Yi-Chen; Hsu, Po-Kuei; Huang, Chien-Sheng; Hsieh, Chih-Cheng; Hsu, Han-Shui.
Afiliación
  • Liu C; Division of Thoracic Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Wang LC; Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Chen HS; Department of Health Care Administration, Chang Jung Christian University, Tainan City, Taiwan.
  • Yeh YC; Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Hsu PK; Division of Thoracic Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Huang CS; School of Medicine, National Yang-Ming Chiao Tung University, Taiwan.
  • Hsieh CC; Division of Thoracic Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Hsu HS; School of Medicine, National Yang-Ming Chiao Tung University, Taiwan.
Thorac Cancer ; 13(14): 2005-2013, 2022 07.
Article en En | MEDLINE | ID: mdl-35680127
ABSTRACT

BACKGROUND:

To evaluate the long-term outcomes after surgical resection for stage I lung adenocarcinoma based on the percentage of lepidic component (LC) and invasive tumor size (IS).

METHODS:

The clinicopathological characteristics of 1049 patients with stage I lung adenocarcinoma who underwent surgery between 2006 and 2016 were retrospectively reviewed. Tumors were categorized into groups A (LC ≥ 50%) and B (LC < 50%). Groups A0 and A1 consisted of minimally invasive adenocarcinomas (MIA) and other lepidic-predominant invasive adenocarcinomas, respectively. Group B was categorized into B1 (IS ≤ 1 cm), B2 (1 < IS≤2 cm), and B3 (2 < IS≤3 cm) by invasive tumor size and divided into subgroups (B1[lep+]/[lep-], B2[lep+]/[lep-], and B3[lep+]/[lep-]) according to the presence[lep+] or absence[lep-] of LCs. Cumulative incidence of recurrence (CIR) and cancer-specific survival (CSS) were examined.

RESULTS:

LC decreased with increasing IS. Only 24 (8.5%) tumors in group A had an IS >1 cm. 10-year CIR and CSS were 15.2% and 86.0%. LC and IS were found to be independent predictors of CSS. Patients in group A had 1.4% 10-year CIR and 100% 10-year CSS. In group B, a significantly higher CIR and worse CSS were observed as IS increased (p < 0.001), but LC was not a predictor for CSS (p = 0.593). No significant differences in CIR or CSS were found in presence of LC or not when LC < 50% (B1[lep+]/[lep-], B2[lep+]/[lep-], and B3[lep+]/[lep-] p = 0.36/0.48, p = 0.82/0.94, and p = 0.90/0.37, respectively).

CONCLUSIONS:

LC≥50% tumors demonstrated excellent prognosis regardless of IS. The outcomes of LC < 50% tumors were well predicted by IS, corresponding to the T-staging system. The predictive value of LC for prognosis became insignificant.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Adenocarcinoma / Adenocarcinoma del Pulmón / Neoplasias Pulmonares Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Thorac Cancer Año: 2022 Tipo del documento: Article País de afiliación: Taiwán

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Adenocarcinoma / Adenocarcinoma del Pulmón / Neoplasias Pulmonares Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Thorac Cancer Año: 2022 Tipo del documento: Article País de afiliación: Taiwán